Research ArticleBasic Sciences
Strontium-89 Therapy: Measurement of Absorbed Dose to Skeletal Metastases
Glen M. Blake, Maureen A. Zivanovic, Richard M. Blaquiere, David R. Fine, Alexander J. McEwan and Duncan M. Ackery
Journal of Nuclear Medicine April 1988, 29 (4) 549-557;
Glen M. Blake
Maureen A. Zivanovic
Richard M. Blaquiere
David R. Fine
Alexander J. McEwan


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Strontium-89 Therapy: Measurement of Absorbed Dose to Skeletal Metastases
Glen M. Blake, Maureen A. Zivanovic, Richard M. Blaquiere, David R. Fine, Alexander J. McEwan, Duncan M. Ackery
Journal of Nuclear Medicine Apr 1988, 29 (4) 549-557;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer
- Bone-Seeking Radionuclides For Therapy
- Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate
- Effects of Low-Dose Cisplatin on 89Sr Therapy for Painful Bone Metastases from Prostate Cancer: A Randomized Clinical Trial
- Therapy of Metastatic Bone Pain
- Quantitative Bone Single-Photon Emission Computed Tomography for Prediction of Pain Relief in Metastatic Bone Disease Treated With Rhenium-186 Etidronate